Onconetix, Inc.
ONCO evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $3.3M
- Lead Asset:
- entadfi (Approved)
What it means
What to watch
Prepared research question
What matters most for ONCO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ONCO
Onconetix, Inc. (ONCO) is a pre-revenue biotech company focused on commercializing its Proclarix product in Europe while facing significant capital constraints and ongoing net losses.
Key risk: Cash runway risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$3.3M
Cash Runway
—
Lead Asset
entadfi (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Onconetix, Inc..
Onconetix, Inc. (ONCO) is a pre-revenue biotech company focused on commercializing its Proclarix product in Europe while facing significant capital constraints and ongoing net losses.
- Onconetix reported total revenue of $0.0M and net income of -$2.9M as of 2026-06-30 [sec].
- The company had cash of approximately $3.7 million as of March 31, 2026, and an accumulated deficit of approximately $135.4 million [sec_mda · as of 2026-05-13].
- Proclarix is CE-marked and for sale in Europe; the company continues sales efforts and expects growing revenues from Proclarix in 2026 and beyond [sec_mda · as of 2026-03-13].
- Onconetix has incurred net losses since inception and expects to continue incurring net losses [sec · filed 2026-08-31].
- The company's current cash balance is not sufficient to fund operations through the end of December 2026 [sec_mda · as of 2026-05-13].
What works
- Proclarix is CE-marked and already for sale in Europe, providing a potential near-term revenue stream [sec_mda · as of 2026-03-13].
- The company has a working capital surplus of approximately $1.3 million as of March 31, 2026, indicating some short-term liquidity [sec_mda · as of 2026-05-13].
- Onconetix has secured multiple equity financings (Series D and Series E Preferred Stock) in 2025 to support operations [sec_mda · as of 2026-05-13].
What to weigh
- Onconetix has no revenue and continues to generate net operating losses, with a net income of -$2.9M as of 2026-06-30 [sec].
- The company's cash balance is insufficient to fund operations through the end of 2026, and there are no committed sources of additional financing [sec_mda · as of 2026-05-13].
- The company's accumulated deficit is approximately $135.4 million as of March 31, 2026, reflecting substantial historical losses [sec_mda · as of 2026-05-13].
- Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the date of issuance of the 2025 financial statements [sec_mda · as of 2026-03-13].
From the filings
Quoted directly from source documents.
Cash position and accumulated deficit as of March 31, 2026.
“As of March 31, 2026, the Company had cash of approximately $3.7 million, a working capital surplus of approximately $1.3 million and an accumulated deficit of approximately $135.4 million.”
SEC MD&A · May 13, 2026
Proclarix is CE-marked and for sale in Europe.
“Proclarix is CE-marked and for sale in Europe.”
SEC MD&A · March 13, 2026
Cash is insufficient to fund operations through end of 2026.
“The Company's current cash balance is not sufficient to fund its operations through the end of December 2026.”
SEC MD&A · May 13, 2026
Catalyst timeline
- 2028-08-31 · Phase3_Topline — Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancer; endpoint is overall survival.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash balance insufficient to fund operations through end of 2026; no committed financing sources [sec_mda · as of 2026-05-13].
- Going concern uncertainty — Management expressed substantial doubt about ability to continue as a going concern for one year [sec_mda · as of 2026-03-13].
- No revenue generation — Company has $0 revenue and expects continued net losses; revenue from Proclarix not yet materialized [sec].
- Dependence on external financing — No committed sources of additional capital; future funding uncertain [sec_mda · as of 2025-11-13].
What to watch
- Ability to secure additional equity or debt financing to extend cash runway beyond 2026 [sec_mda · as of 2026-05-13].
- Commercial progress of Proclarix in Europe and whether revenue growth materializes as expected [sec_mda · as of 2026-03-13].
- Closure of the Realbotix Transactions as contemplated in the Share Exchange Agreement [sec_mda · as of 2026-08-13].
- Phase 3 topline results for ONC-392 (catalyst date 2028-08-31) [catalyst].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Onconetix, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Onconetix, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.22 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
1 buy · 3 sells (180d)
Pipeline
Financials
Short Interest
as of Apr 28, 2026- % of float
- 33.1%
- Days to cover
- 0.0
- Shares short
- 228,855
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ONCO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Onconetix, Inc.?
Onconetix, Inc. (ONCO) is a pre-revenue biotech company focused on commercializing its Proclarix product in Europe while facing significant capital constraints and ongoing net losses.
What is Onconetix, Inc.'s lead drug candidate?
Onconetix, Inc.'s most advanced tracked candidate is entadfi (Approved) for BPH (benign prostatic hyperplasia).
Who is the CEO of Onconetix, Inc.?
Mr. David Allan White C.A., C.P.A., ICD.D is the chief executive officer of Onconetix, Inc. (ONCO).
Where is Onconetix, Inc. headquartered?
Onconetix, Inc. (ONCO) is headquartered in Cincinnati, OH, United States.
What therapeutic areas does Onconetix, Inc. focus on?
Onconetix, Inc. develops therapies across Oncology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.